Management of Hepatic Encephalopathy (HE)

Definition and Overview

• Altered blood-brain barrier permeability
• Enhanced GABA-benzodiazepine receptor sensitivity (neurosteroid-mediated)
• Astrocyte swelling (from glutamine accumulation) causing cerebral edema
• Systemic inflammation amplifying ammonia neurotoxicity
• Contributions from serotonin, nitric oxide, manganese, and oxidative stress

Classification

By Underlying Disease (West Haven + SONIC)

Grading: West Haven Criteria / SONIC

• Covert HE (grades 0-1): detectable only with neuropsychometric or neurophysiologic tests; affects ~50% of all cirrhotics
• Overt HE (grade ≥2): clinically apparent; requires active treatment

Step 1: Identify and Treat Precipitating Factors

Always look for the underlying cause of worsening hepatic encephalopathy. - Symptom to Diagnosis, 4th Ed.

Step 2: Ammonia-Reducing Pharmacotherapy

A. Lactulose (First-Line)

• Mechanism: Non-absorbable synthetic disaccharide; metabolized by colonic bacteria to lactic acid → acidifies the colon → traps NH₃ as NH₄⁺ → excreted in stool; also inhibits glutamine-dependent ammonia production in gut wall; has direct cathartic effect
• Dosing (acute episode):
  • PO: 30-45 mL every 1-2 hours initially until bowel movements begin, then titrate to 3-5 soft stools/day (Washington Manual: 15-45 mL bid-qid)
  • Nasogastric tube if unable to take orally
  • Enema: 300 mL lactulose + 700 mL water/NS; retain 30 minutes (for comatose/obtunded patients)
• Target: 2-3 soft stools per day
• Adverse effects: Flatulence, diarrhea, hypovolemia, hypernatremia (from excessive loss)
• Contraindication: Active ileus or bowel obstruction (oral form)
• Blood ammonia can decrease by up to 50% with lactulose therapy

B. Rifaximin (First-Line Adjunct / Secondary Prophylaxis)

• Mechanism: Minimally absorbed, broad-spectrum macrolide antibiotic; reduces ammonia-producing gut flora
• Dose: 550 mg PO twice daily (some sources: 400 mg every 8 hours)
• Evidence: Adding rifaximin to lactulose achieves complete HE reversal in 76% vs. 50.8% and reduces mortality (23.1% vs. 49.1%) compared to lactulose alone (Mulholland & Greenfield's Surgery, 7e)
• In a placebo-controlled trial, rifaximin significantly reduced the risk of breakthrough HE episodes and first hospitalization over 6 months (Washington Manual)
• Role: Add rifaximin if no improvement within first 24 hours of lactulose therapy, OR for all patients on secondary prophylaxis after an overt episode
• Tolerability: Best tolerated of all antibiotic options; low systemic absorption minimizes adverse effects

C. Other Antibiotics (Second-Line, Limited Use)

Step 3: Nutritional Management

• Protein restriction is NOT recommended - it worsens sarcopenia, increases mortality, and does not reliably reduce ammonia in modern practice
• Target: 1.2-1.5 g/kg/day of protein; maintain adequate caloric intake
• Branched-chain amino acids (BCAAs): IV infusion has shown benefit without increased mortality in HE; BCAAs can be metabolized peripherally, bypassing the liver. Used in patients intolerant of standard protein (Rosen's Emergency Medicine)
• Small frequent meals (4-6/day) including a late-night carbohydrate snack to reduce fasting catabolism
• Vegetable/dairy protein preferred over animal protein in severe cases (produces less ammonia)
• Zinc supplementation: Zinc is a cofactor in the urea cycle; deficiency common in cirrhotics and may worsen HE

Step 4: Management of Cerebral Edema (ALF/Grade 3-4 HE)

• ICP monitoring in selected patients
• Head elevation to 30°
• Mannitol infusion (osmotherapy)
• Hypertonic saline to maintain serum sodium 145-155 mEq/L
• Avoid fever, seizures (treat with levetiracetam), hypotension
• N-acetylcysteine: ameliorates IL-17-mediated inflammation; improves transplant-free survival in ALF (Plum & Posner)

Step 5: Secondary Prophylaxis (Prevention of Recurrence)

• Lactulose (titrated to 2-3 stools/day) - first-line
• Rifaximin 550 mg PO bid added to lactulose for secondary prophylaxis - superior combination
• Continue indefinitely; stopping increases recurrence risk substantially
• For minimal/covert HE: management approach is evolving; consider treatment especially if it affects daily functioning or driving

Step 6: Treatment of Refractory / Persistent HE

• Eliminate precipitants again systematically
• TIPS reduction/occlusion: Transjugular intrahepatic portosystemic shunts can cause or worsen HE; stent diameter reduction or occlusion may be considered
• Portosystemic shunt embolization: For type B HE or large spontaneous shunts
• L-ornithine L-aspartate (LOLA): Promotes ammonia detoxification; used in some centers
• Zinc supplementation: Particularly in deficient patients
• Fecal microbiota transplantation (FMT): Emerging therapy targeting the gut microbiome

Step 7: Definitive Therapy - Liver Transplantation

• Liver transplantation generally reverses HE - it is the only definitive treatment
• HE is a major indication for listing; overt HE has MELD score implications
• Patients should be evaluated for LT after the first episode of overt HE, as 1-year survival is only 42% without it

Differential Diagnosis (Exclusion Required)

• Hypoglycemia
• Hypo/hypernatremia
• Intracranial hemorrhage (subdural hematoma - especially in coagulopathic cirrhotics)
• Drug toxicity / accidental overdose (opioids, benzodiazepines - reduced hepatic clearance)
• Wernicke-Korsakoff syndrome (nutritional encephalopathy)
• Meningitis / septic encephalopathy
• Basilar artery thrombosis (mimics due to motor signs in rapid-onset HE)

Management Summary Algorithm

Overt HE Episode
       ↓
1. IDENTIFY + TREAT PRECIPITANT (GI bleed, infection, electrolytes, meds)
       ↓
2. START LACTULOSE (30-45 mL q1-2h until bowel movement, then titrate)
   + Enema if comatose
       ↓
3. ADD RIFAXIMIN if no improvement at 24h OR for maintenance
       ↓
4. Nutritional support (1.2-1.5 g/kg protein, BCAAs if needed)
       ↓
5. Grade 3-4 / ALF → Cerebral edema management, ICP monitoring, NAC
       ↓
6. After resolution → INDEFINITE secondary prophylaxis (lactulose ± rifaximin)
       ↓
7. EVALUATE FOR LIVER TRANSPLANTATION

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Chapter 94 (HE classification, pathophysiology, West Haven/SONIC grading, management)
• Washington Manual of Medical Therapeutics (lactulose and rifaximin dosing)
• Mulholland and Greenfield's Surgery, 7e (rifaximin + lactulose evidence, RCT data)
• Rosen's Emergency Medicine (precipitants, BCAA, electrolyte management)
• Tintinalli's Emergency Medicine (diagnosis of exclusion, lactulose mechanism)
• Plum and Posner's Diagnosis and Treatment of Stupor and Coma (ALF vs. chronic HE, cerebral edema, NAC)
• Symptom to Diagnosis, 4e (treatment algorithm, prophylaxis)
• Bradley and Daroff's Neurology in Clinical Practice (West Haven scale, epidemiology)

Recent evidence note (PubMed 2024-2026): A 2025 meta-analysis (PMID 40812534) found that PPI use is associated with increased risk of HE in cirrhotic patients - review and minimize PPI use in at-risk patients where possible.